215 related articles for article (PubMed ID: 15946581)
1. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Byrne BJ; Garst J
Curr Oncol Rep; 2005 Jul; 7(4):241-7. PubMed ID: 15946581
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
7. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Fuster LM; Sandler AB
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Thomas M
Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
[TBL] [Abstract][Full Text] [Related]
9. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
10. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
Clark GM; Zborowski DM; Santabarbara P; Ding K; Whitehead M; Seymour L; Shepherd FA;
Clin Lung Cancer; 2006 May; 7(6):389-94. PubMed ID: 16800964
[TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib andĀ Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFRĀ Mutations.
Zenke Y; Yoh K; Matsumoto S; Umemura S; Niho S; Ohmatsu H; Goto K; Ohe Y
Clin Lung Cancer; 2016 Sep; 17(5):412-418. PubMed ID: 26944770
[TBL] [Abstract][Full Text] [Related]
12. Role of tyrosine kinase inhibitors in lung cancer.
Ansari J; Palmer DH; Rea DW; Hussain SA
Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
14. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
[TBL] [Abstract][Full Text] [Related]
15. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Wong AS; Soong R; Seah SB; Lim SW; Chuah KL; Nga ME; Chin TM; Soo RA
J Thorac Oncol; 2008 Apr; 3(4):400-4. PubMed ID: 18379359
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Lee VW; Schwander B; Lee VH
Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
[TBL] [Abstract][Full Text] [Related]
17. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Curr Med Res Opin; 2015 Jan; 31(1):25-33. PubMed ID: 25329826
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
20. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
Natale RB
Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S11-7. PubMed ID: 14641989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]